ClinicalTrials.gov

History of Changes for Study: NCT03281369
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA)
Latest version (submitted October 26, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 September 11, 2017 None (earliest Version on record)
2 October 20, 2017 Recruitment Status, Study Status, Contacts/Locations and Study Identification
3 November 3, 2017 Study Status
4 January 8, 2018 Study Status and Sponsor/Collaborators
5 February 13, 2018 Contacts/Locations and Study Status
6 March 15, 2018 Study Status and Contacts/Locations
7 April 12, 2018 Study Status
8 May 10, 2018 Study Status and Contacts/Locations
9 June 8, 2018 Study Status
10 July 9, 2018 Contacts/Locations and Study Status
11 August 3, 2018 Study Status
12 November 2, 2018 Contacts/Locations and Study Status
13 December 11, 2018 Study Status and Contacts/Locations
14 February 18, 2019 Contacts/Locations and Study Status
15 March 20, 2019 Study Status
16 April 18, 2019 Contacts/Locations and Study Status
17 June 3, 2019 Study Status
18 June 10, 2019 Contacts/Locations and Study Status
19 October 25, 2019 Sponsor/Collaborators, Contacts/Locations and Study Status
20 November 18, 2019 Study Status and Contacts/Locations
21 December 9, 2019 Study Status
22 January 6, 2020 Study Status
23 February 4, 2020 Study Status
24 March 3, 2020 Study Status
25 April 2, 2020 Arms and Interventions, Outcome Measures, Study Status, Study Identification, Eligibility, Study Design, Conditions and Study Description
26 May 18, 2020 Contacts/Locations and Study Status
27 June 8, 2020 Study Status
28 June 29, 2020 Contacts/Locations and Study Status
29 July 20, 2020 Study Status
30 August 11, 2020 Study Status and Contacts/Locations
31 September 8, 2020 Contacts/Locations and Study Status
32 October 26, 2020 Study Status and Contacts/Locations
33 November 18, 2020 Study Status and Contacts/Locations
34 December 14, 2020 Contacts/Locations and Study Status
35 January 7, 2021 Study Status
36 February 4, 2021 Contacts/Locations and Study Status
37 March 2, 2021 Study Status and Contacts/Locations
38 April 26, 2021 Study Status
39 May 17, 2021 Contacts/Locations and Study Status
40 June 21, 2021 Contacts/Locations and Study Status
41 July 13, 2021 Study Status
42 August 26, 2021 Arms and Interventions, Study Status, Contacts/Locations, Eligibility and Outcome Measures
43 September 21, 2021 Study Status and Contacts/Locations
44 October 13, 2021 Study Status
45 November 13, 2021 Contacts/Locations and Study Status
46 December 7, 2021 Study Status and Contacts/Locations
47 January 14, 2022 Study Status
48 February 11, 2022 Study Status
49 March 11, 2022 Study Status
50 April 5, 2022 Study Status and Contacts/Locations
51 May 5, 2022 Study Status
52 June 14, 2022 Study Status and Contacts/Locations
53 July 8, 2022 Study Status and Contacts/Locations
54 July 29, 2022 Contacts/Locations and Study Status
55 August 25, 2022 Study Status
56 September 29, 2022 Study Status
57 October 26, 2022 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT03281369
Submitted Date:  September 11, 2017 (v1)

Open or close this module Study Identification
Unique Protocol ID: YO39609
Brief Title: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA)
Official Title: A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)
Secondary IDs: 2016-004529-17 [EudraCT Number]
Open or close this module Study Status
Record Verification: September 2017
Overall Status: Not yet recruiting
Study Start: November 15, 2017
Primary Completion: November 13, 2021 [Anticipated]
Study Completion: November 13, 2021 [Anticipated]
First Submitted: September 11, 2017
First Submitted that
Met QC Criteria:
September 11, 2017
First Posted: September 13, 2017 [Actual]
Last Update Submitted that
Met QC Criteria:
September 11, 2017
Last Update Posted: September 13, 2017 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Hoffmann-La Roche
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring:
Open or close this module Study Description
Brief Summary: A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the second-line (2L) Cohort will consist of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Cohort will consist of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms.
Detailed Description:
Open or close this module Conditions
Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1/Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 9
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 357 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Active Comparator: 1L-Control: mFOLFOX6
Participants in the 1L Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Drug: 5-Fluorouracil (5-FU)
5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
Drug: Leucovorin
Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Folinic acid
Drug: Oxaliplatin
Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
Experimental: 1L-A: mFOLFOX6 + Atezo + Cobi
Participants in the 1L-A arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib.
Drug: 5-Fluorouracil (5-FU)
5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
Drug: Leucovorin
Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Folinic acid
Drug: Oxaliplatin
Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
Biological: Atezolizumab
Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Tecentriq
Drug: Cobimetinib
Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
Other Names:
  • Cotellic
Experimental: 1L-A2: Atezo + mFOLFOX6 followed by Atezo + Cobi
Participants in the 1L-A2 arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond.
Drug: 5-Fluorouracil (5-FU)
5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
Drug: Leucovorin
Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Folinic acid
Drug: Oxaliplatin
Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
Biological: Atezolizumab
Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Tecentriq
Drug: Cobimetinib
Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
Other Names:
  • Cotellic
Experimental: 1L-B: mFOLFOX6 + Atezo
Participants in the 1L-B arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Drug: 5-Fluorouracil (5-FU)
5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
Drug: Leucovorin
Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Folinic acid
Drug: Oxaliplatin
Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
Biological: Atezolizumab
Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Tecentriq
Active Comparator: 2L-Control: Ramucirumab + Paclitaxel
Participants in the 2L Control arm will receive ramucirumab plus paclitaxel. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Biological: Ramucirumab
Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
Drug: Paclitaxel
Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Experimental: 2L-1: Atezo + Cobi
Participants in the 2L-1 arm will receive atezolizumab in combination with cobimetinib.
Biological: Atezolizumab
Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
Other Names:
  • Tecentriq
Drug: Cobimetinib
Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
Other Names:
  • Cotellic
Experimental: 2L-2: Atezo + PEGPH20
Participants in the 2L-2 arm will receive atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Biological: PEGylated recombinant human hyaluronidase (PEGPH20)
PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
Biological: Atezolizumab
Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
Other Names:
  • Tecentriq
Experimental: 2L-3: Atezo + BL-8040
Participants in the 2L-3 arm will receive atezolizumab in combination with BL-8040. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Drug: BL-8040
BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
Biological: Atezolizumab
Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
Other Names:
  • Tecentriq
Experimental: 2L-4: Atezo + Linagliptin
Participants in the 2L-4 arm will receive atezolizumab in combination with linagliptin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
Drug: Linagliptin
Linagliptin: 5 mg orally once a day of every 21-day cycle.
Biological: Atezolizumab
Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
Other Names:
  • Tecentriq
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)
[ Time Frame: From Randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]

2. Percentage of Participants with Adverse Events (AEs)
[ Time Frame: From first study treatment administration until 30 days after the last dose or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 3-5 years) ]

3. For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs
[ Time Frame: During the safety run-in phase up to 28 days ]

Secondary Outcome Measures:
1. Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1
[ Time Frame: From randomization up to the first occurrence of disease (up to approximately 3-5 years) ]

2. Overall Survival (OS)
[ Time Frame: From randomization up to death from any cause (up to approximately 3-5 years) ]

3. Percentage of Participants Who Are Alive at Month 6 and at Month 12
[ Time Frame: Month 6, Month 12 ]

4. Duration of Response, as Determined by Investigator According to RECIST v1.1
[ Time Frame: From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) ]

5. Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1
[ Time Frame: From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]

6. Serum Concentration of Atezolizumab
[ Time Frame: Pre-infusion (0 hour [hr]), 30 minutes (min) post-infusion (infusion=60 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-5 years) ]

7. Plasma Concentration of Cobimetinib
[ Time Frame: Prior to cobimetinib dose, 2-4 hr after cobimetinib dose on Day 15 of Cycle 1 (cycle length=28 days) ]

8. Plasma Concentration of PEGPH20
[ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days and 120 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]

Pre-infusion (0 hr), 5 min and 1-3 hrs post infusion (infusion duration=10-12 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Days 8 and 15 of Cycle 1, Day 1 of Cycles 3, 4, 8, 12, 16; pre-infusion (0 hr) and 5 min post-infusion on Day 1 of Cycle 2 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-5 years)
9. Plasma Concentration of BL-8040
[ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]

Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1); 1 hr post-dose on Days 1, 5 of priming period; pre-dose (0 hr), 1 hour post-dose on Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16; pre-dose (0 hr) on Day 1 of Cycle 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-5 years); 30 days after last dose (up to approximately 3-5 years)
10. Plasma Concentration of Linagliptin
[ Time Frame: 2 hr postdose oral linagliptin on Day 1 of Cycle 1, prior to atezolizumab infusion and predose oral linagliptin on Day 15 of Cycle 1 as well as on Day 1 of Cycles 2, 3, and 4 ]

11. Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab
[ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-5 years) ]

12. Percentage of Participants With ADA to PEGPH20
[ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-5 years) ]

13. Percentage of Participants With ADA to BL-8040
[ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]

Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Cycle 1 Day 1), Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16, 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-5 years); 30 days after last dose (up to approximately 3-5 years)
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Age >/= 18 years;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  • Life expectancy >/= 3 months, as determined by the investigator;
  • Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma of gastric or gastroesophageal junction; (for the 1L Cohort: no prior systemic therapy for the locally advanced or metastatic disease; for the 2L Cohort: disease progression during or following a first-line platinum-containing or fluoropyrimidine-containing chemotherapy regimen);
  • Only for the 1L Cohort: human epidermal growth factor receptor 2 (HER2)-negative tumors;
  • Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);
  • Adequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment;
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm;
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm.

Exclusion Criteria:

Exclusion criteria for the 2L Cohort:

  • Urinary protein is > 1 + on dipstick and the required following 24-hour urine collection shows urinary protein > 2000 mg;
  • Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment;
  • History of gastrointestinal perforation and/or fistulae within 6 months prior to initiation of study treatment;
  • Presence of a bowel obstruction, history or presence of inflammatory enteropathy, or extensive intestinal resection, Crohn disease, ulcerative colitis, or chronic diarrhea;
  • Uncontrolled arterial hypertension >/= 150/ >/= 90 millimeter of mercury (mmHg) despite standard medical management;
  • Chronic therapy with non-steroidal anti-inflammatory agents or other anti-platelet agents.

Exclusion Criteria:

  • Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy;
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;
  • History of leptomeningeal disease;
  • Active or history of autoimmune disease or immune deficiency;
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan;
  • Positive test for human immunodeficiency virus (HIV) at screening;
  • Active hepatitis B virus (HBV) or hepatitis C (HCV) infection;
  • Severe infection within 4 weeks prior to initiation of study treatment;
  • Significant cardiovascular disease;
  • Significant bleeding disorder;
  • Prior allogeneic stem cell or solid organ transplantation;
  • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study;
  • Treatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar agents for therapeutic purposes;
  • History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death;
  • Known allergy or hypersensitivity to any of the study drugs or their excipients.
Open or close this module Contacts/Locations
Locations: United States, Arizona
Mayo Clinic Cancer Center
Scottsdale, Arizona, United States, 85259
United States, California
Uni of Southern California; Norris Comprehensive Cancer Ctr
Los Angeles, California, United States, 90033
United States, Massachusetts
Dana-Farber Cancer Institute - Gastrointestinal Cancer Treatment Center
Boston, Massachusetts, United States, 02111
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
France
Centre Leon Berard
Lyon, France, 69008
Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE
Toulouse, France, 31100
Gustave Roussy Cancer Campus
Villejuif, France, 94805
Germany
Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung)
Essen, Germany, 45122
Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)
Frankfurt am Main, Germany, 60488
Universitatsklinik Heidelberg; Universit├Ątshautklinik und Nationales Centrum f├╝r Tumorerkrankungen
Heidelberg, Germany, 69120
Korea, Republic of
Seoul National University Hospital (SNUH) - Medical Oncology Center
Jongno -Gu, Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 06351
Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center; Cancer Metastasis Research Center
Seoul, Korea, Republic of
University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)
Songpa-gu, Korea, Republic of
Netherlands
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands, 1066 CX
Spain
Hospital Universitari Vall dHebron - Vall dHebron Institut dOncologia (VHIO)
Barcelona, Spain
Spain, Navarra
Universidad de Navarra - Clinica Universitaria de Navarra (CUN)
Pamplona, Navarra, Spain, 31008
Taiwan
National Taiwan University Hospital (NTUH) - Cancer Research Center
Taipei, Taiwan
United Kingdom
Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM
London, United Kingdom, 0
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
Sutton, United Kingdom, SM2 5PT
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services